Skip to main content
. Author manuscript; available in PMC: 2015 Feb 14.
Published in final edited form as: J Urol. 2010 Sep 17;184(5):1907–1913. doi: 10.1016/j.juro.2010.06.148

Table 2.

Detection endpoints

HAL fluorescence group, n=365 (ITT Detection)

Total, n (% of patients in the ITT Detection group with stated tumor type) Patients with at least one lesion of each type detected only with fluorescence
Patients with Ta or T1 tumors 286 (78.4%) 47 (16.4%)
(95% CI: 12.3 – 21.2)%
Patients with Ta tumors 262 (71.8%) 41 (15.6%)
Patients with T1 tumors 63 (17.3%) 8 (12.7%)
Patients with CIS 41 (11.2%) 19 (46.3%)

Note: patients may have more than one tumor type